Scarica l'app Stockscreener
40.63
5.09%
-2.18
Dopo l'orario di chiusura:
39.50
-1.13
-2.78%
Precedente Chiudi:
$42.81
Aprire:
$41.03
Volume 24 ore:
1.69M
Relative Volume:
1.57
Capitalizzazione di mercato:
$2.48B
Reddito:
-
Utile/perdita netta:
$-229.97M
Rapporto P/E:
-9.3977
EPS:
-4.3234
Flusso di cassa netto:
$-136.51M
1 W Prestazione:
+2.19%
1M Prestazione:
+48.50%
6M Prestazione:
+202.53%
1 anno Prestazione:
+1,422%
Intervallo 1D:
$38.68
$42.49
Intervallo di 1 settimana:
$33.35
$45.60
Portata 52W:
$1.92
$45.60
Kodiak Sciences Inc Stock (KOD) Company Profile
Nome
Kodiak Sciences Inc
Settore
Industria
Telefono
650-281-0850
Indirizzo
1250 PAGE MILL RD, PALO ALTO, CA
Compare KOD vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KOD
Kodiak Sciences Inc
|
40.63 | 2.48B | 0 | -229.97M | -136.51M | -4.3234 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Kodiak Sciences Inc Stock (KOD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-11 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-10-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-09-25 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2025-09-22 | Iniziato | Jefferies | Buy |
| 2025-08-14 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2024-12-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-09-05 | Iniziato | H.C. Wainwright | Neutral |
| 2023-12-11 | Ripresa | Goldman | Sell |
| 2023-11-17 | Aggiornamento | CapitalOne | Equal Weight → Overweight |
| 2023-07-27 | Downgrade | UBS | Buy → Neutral |
| 2023-07-25 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2023-07-25 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-07-24 | Downgrade | CapitalOne | Overweight → Equal Weight |
| 2023-07-24 | Downgrade | Jefferies | Buy → Hold |
| 2022-11-15 | Iniziato | CapitalOne | Overweight |
| 2022-08-02 | Downgrade | Citigroup | Neutral → Sell |
| 2022-02-24 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-02-11 | Iniziato | Goldman | Buy |
| 2022-02-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2021-03-12 | Iniziato | Evercore ISI | Outperform |
| 2021-03-01 | Downgrade | Barclays | Equal Weight → Underweight |
| 2021-02-17 | Downgrade | ROTH Capital | Buy → Neutral |
| 2021-01-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-12-11 | Iniziato | Citigroup | Neutral |
| 2020-11-30 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-11-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-13 | Downgrade | Goldman | Buy → Neutral |
| 2020-03-31 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-03 | Iniziato | Goldman | Buy |
| 2020-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2020-02-06 | Iniziato | SunTrust | Buy |
| 2020-01-08 | Iniziato | ROTH Capital | Buy |
| 2020-01-03 | Iniziato | Jefferies | Buy |
| 2019-12-24 | Iniziato | JP Morgan | Overweight |
| 2019-10-15 | Reiterato | Chardan Capital Markets | Buy |
| 2019-02-20 | Iniziato | Chardan Capital Markets | Buy |
| 2018-10-29 | Iniziato | Barclays | Overweight |
| 2018-10-29 | Iniziato | BofA/Merrill | Buy |
| 2018-10-29 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Kodiak Sciences Inc Borsa (KOD) Ultime notizie
Kodiak Sciences | 10-K: FY2025 Annual Report - Moomoo
Kodiak Sciences Faces Going Concern Warning As Valuation Gap Persists - Sahm
Lifesci Capital Trims Earnings Outlook for Kodiak Sciences - National Today
Q1 EPS Estimates for Kodiak Sciences Decreased by Analyst - marketbeat.com
Lifesci Capital Forecasts Lower Earnings for Kodiak Sciences - marketbeat.com
Kodiak Sciences CFO Borgeson sells $1.2m in shares By Investing.com - Investing.com India
Kodiak Sciences CFO Borgeson sells $1.2m in shares - Investing.com
Kodiak Sciences (KOD) CFO exercises 30K options and sells 30K shares under 10b5-1 plan - Stock Titan
Kodiak Sciences Inc. (KOD) stock price, news, quote and history - Yahoo Finance UK
[144] Kodiak Sciences Inc. SEC Filing - Stock Titan
Point72 reports 609,806 shares in Kodiak (KOD) — 1.0% stake - Stock Titan
Kodiak Sciences Inc. (KOD) options chain - Yahoo Finance Singapore
Kodiak Sciences (KOD) Sees Decline as Stock Falls 8.7% - gurufocus.com
Here's Why We're Not Too Worried About Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation - Moomoo
Kodiak Sciences Inc. (KOD) Latest Stock News & Headlines - Yahoo! Finance Canada
Fed Meeting: Can Kodiak Sciences Inc lead its sector in growthQuarterly Market Summary & Breakout Confirmation Trade Signals - baoquankhu1.vn
Kodiak Sciences 2025 Financial Update - AlphaStreet
Kodiak Sciences (KOD) Reports Positive Developments in Q4 Results - GuruFocus
Kodiak Sciences (KOD) Shares Surge Over 10% - GuruFocus
Kodiak Q4 Loss Wider Than Expected, Pipeline Development in Focus - TradingView
Kodiak Sciences Stock Soars Amid Positive Phase 3 Findings - StocksToTrade
Kodiak Sciences Stock (KOD) Rallies as Analysts Weigh In After Earnings - TipRanks
Why Kodiak Sciences Stock Is Suddenly Surging - TipRanks
Kodiak climbs on late-stage trial win for diabetic retinopathy therapy - MSN
Kodiak Sciences (NASDAQ:KOD) Announces Quarterly Earnings Results, Misses Expectations By $0.02 EPS - marketbeat.com
Kodiak Sciences Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - MarketScreener
Kodiak Sciences (NASDAQ: KOD) outlines retinal pipeline and going-concern risk - Stock Titan
Phase 3 win and 2027 cash runway for Kodiak Sciences (NASDAQ: KOD) - stocktitan.net
Kodiak Sciences Q4 net loss widens on higher R&D spending - TradingView
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results - Bitget
BRIEF-Kodiak Sciences Q4 Net Income USD -56.736 Million - TradingView
Press Release: Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results - Moomoo
Kodiak Sciences (NASDAQ:KOD) Trading 8.3% HigherHere's Why - marketbeat.com
Kodiak Sciences stock is surging Friday: What's driving the action? - MSN
Kodiak Sciences (KOD) climbs 75% on stellar clinical results - msn.com
Kodiak Sciences stock hits 52-week highhere's why - MSN
MACD Signal: Can Kodiak Sciences Inc grow without dilution2026 Risk Factors & Real-Time Volume Spike Alerts - baoquankhu1.vn
Kodiak Sciences Inc. Auditor Raises 'Going Concern' Doubt - MarketScreener
Kodiak Sciences (NASDAQ:KOD) Trading Down 7.8%Time to Sell? - marketbeat.com
Kodiak Sciences: Road To $120 - Forbes
Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC Filing - AOL.com
Kodiak Sciences (KOD) Is Up 66.3% After Strong Zenkuda GLOW2 Phase 3 DataHas The Bull Case Changed? - Yahoo Finance
Kodiak Sciences (KOD) Is Up 66.3% After Zenkuda’s Phase 3 Win in Diabetic Retinopathy - simplywall.st
Kodiak Sciences (KOD) CEO exercises 300,000 stock options into common shares - Stock Titan
KOD Shares Surge Following Encouraging Phase III Results for Eye Disorder Treatment Candidate - Bitget
KOD Stock Soars on Promising Phase III Data for Eye Disease Candidate - The Globe and Mail
H.C. Wainwright raises Kodiak Sciences stock price target on trial data - Investing.com UK
Kodiak Sciences: A Promising Breakthrough in Diabetic Retinopathy Trials - timothysykes.com
Kodiak Sciences (NASDAQ:KOD) Shares Gap Up After Analyst Upgrade - MarketBeat
Kodiak Sciences (NASDAQ:KOD) Price Target Raised to $80.00 - MarketBeat
Kodiak Sciences: Shares Up On Positive Eye Disease DataBut I Remain On Sidelines (KOD) - Seeking Alpha
Kodiak Sciences Inc Azioni (KOD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):